This case report suggests that RNF43 mutations represent a promising biomarker that warrants further validation for its potential in helping prioritize therapy combinations in selected lung cancer patients with BRAFV600E who are most likely to benefit and in identifying those patients for whom alternative treatment approaches are needed. This evidence concerns the gene RNF43 and lung carcinoma.